Am J Transl Res. 2026 Mar 15;18(3):2247-2255. doi: 10.62347/OEUA7949. eCollection 2026.
ABSTRACT
OBJECTIVE: This study intended to clarify the role of metoprolol-spironolactone combination in treating coronary heart disease (CHD) with concurrent heart failure (HF), focusing on its impact on cardiac function.
METHODS: A total of 100 CHD + HF patients were selected, including 50 cases in the control group treated with spironolactone and 50 cases in the research group given metoprolol + spironolactone. Cardiac function (left ventricular end-systolic diameter [LVESd], left ventricular end-diastolic diameter [LVEDd], left ventricular ejection fraction [LVEF]), cardiac function classification, serum brain natriuretic peptide (BNP), oxidative stress (superoxide dismutase [SOD], malondialdehyde [MDA]), inflammation, hemodynamics (cardiac index/output), effectiveness, and safety were analyzed.
RESULTS: The combination therapy induced a more evident reduction in LVESd, LVEDd, BNP, MDA, and two inflammatory cytokines than spironolactone alone, as well as a greater rise in LVEF, SOD, cardiac index, and cardiac output. The research group also showed superior improvements in cardiac function classification and clinical efficacy, as well as a lower overall adverse effect rate.
CONCLUSION: Metoprolol-spironolactone combination is remarkably effective in treating CHD + HF and significantly improve patients' cardiac function, which merits clinical popularization.
PMID:42007134 | PMC:PMC13090920 | DOI:10.62347/OEUA7949